GSK Partners with Syndivia on Innovative ADC for Prostate Cancer

GSK has signed a global exclusive deal with Syndivia - a privately-held biotech dedicated to developing next-generation antibody-drug conjugates (ADCs) - for the advancement and commercialization of a preclinical ADC for patients with metastatic castration-resistant prostate cancer (mCRPC).

This ADC utilizes Syndivia’s GeminiMab conjugation technology to achieve improved efficacy against tumours while maintaining a robust safety profile.

In preclinical studies of this experimental therapy, a statistically significant reduction in tumour growth was observed without any associated increases in side effects, including at the maximum doses. GSK believes this could ultimately provide a best-in-class treatment option for prostate cancer patients, where potential options, especially in community practice, are limited at this time.

Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: “Prostate cancer represents a significant health burden and an emerging area of growth for GSK, where targeted therapies are urgently needed in metastatic castration-resistant settings.”

Sasha Koniev, Chief Executive Officer, Syndivia, said: “We are proud that GSK will advance this programme on a global scale. This agreement underscores the value of our GeminiMab ADC platform and the opportunity to bring a promising new therapy to patients with pressing unmet medical needs.”

The deal strengthens GSK’s expanding oncology pipeline, which includes ADCs with diverse antigens and payloads, next-generation small molecules, and T-cell engagers. Together with GSK’s B7-H3-targeting ADC, GSK’227, the new candidate reinforces the company’s push to develop innovative treatments across multiple stages of prostate cancer.

Under the terms, Syndivia will receive an upfront payment and milestone payments of up to £268 million, along with tiered royalties on global sales. GSK will take full charge of development, manufacturing, and worldwide commercialization of the ADC, marking a major step forward in next-generation ADC innovation for prostate cancer.